# Preventive Treatment of Oxaliplatin Induced Peripheral Neuropathy in Metastatic Colorectal Cancer (POLAR-M)

> **NCT03654729** · PHASE3 · TERMINATED · sponsor: **Egetis Therapeutics** · enrollment: 291 (actual)

## Conditions studied

- Colorectal Cancer
- Chemotherapy-induced Peripheral Neuropathy

## Interventions

- **DRUG:** Calmangafodipir (2 µmol/kg)
- **DRUG:** Calmangafodipir (5 µmol/kg)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03654729
- **Lead sponsor:** Egetis Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-11-07
- **Primary completion:** 2020-08-31
- **Final completion:** 2020-08-31
- **Target enrollment:** 291 (ACTUAL)
- **Why stopped:** On 23 January 2020, the Sponsor announced that the United States (US) Food and Drug Administration (FDA) had issued a clinical hold in the US of the POLAR program.
- **Last updated:** 2021-12-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03654729

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03654729, "Preventive Treatment of Oxaliplatin Induced Peripheral Neuropathy in Metastatic Colorectal Cancer (POLAR-M)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03654729. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*